Pay in 4 interest-free payments of $5.19 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
The robust growth was driven by expanded use in both early and advanced breast cancer settings, particularly following its approval for adjuvant treatment in high-risk early-stage patients
Am J Cancer Res (2021) 11:101230
Super happy I chose them
Exogenous integrin IIb3 inhibitors revisited: past, present and future applications
The analysis revealed a steady increase from 0.76 to 0.80 million between July 2017 and June 2018 and from 1.29 to 1.51 million between March 2023 and February 2024
If you have any questions or need further information, please contact us at: Business Consulting: Technical Consultation: [email protected] Scan the QR code below to register at our OncoWuXi database for free
US$ 25.53
US$ 28.81
US$ 21.00
